Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edimer Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Edimer Pharmaceuticals Inc. is poised to begin the first human trials of a protein-replacement therapy for XLHED, a disorder that impacts the development of teeth, hair and skin. Although the start-up is planning to test its therapy first in adults, Edimer's ultimate goal is to permanently correct the disorder by treating developing fetuses in utero. The company's compound is designed to cross the placental barrier, so that it can bind an endogenous receptor and trigger normal fetal development with just a single treatment.
Advertisement

Related Content

With $18M In Series B Funds, Edimer To Test Protein-Replacement Therapy
Start-Up Previews (05/2011)
Afraxis Inc.
bluebird bio LLC
Rare Disease Research: Where Compassion Meets Commerce
Ultragenyx Pharmaceutical LLC
Start-Up Previews (05/2011)
Rare Disease Research: Where Compassion Meets Commerce

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092115

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel